MAP1LC3A

Across TCGA pan-cancer cohorts, MAP1LC3A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MAP1LC3A data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MAP1LC3A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP1LC3A expression acts as an unfavorable survival marker.

COAD, LUAD, and UCEC are the cancer types where MAP1LC3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.019	0.791	<.001	18	view →
LUAD	OS	Median	All	0.257	0.812	.003	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MAP1LC3A–COAD (DFS)

Open the COAD breakdown →